249 related articles for article (PubMed ID: 12203665)
1. Recombinant human erythropoietin in pediatric oncology: a review.
Feusner J; Hastings C
Med Pediatr Oncol; 2002 Oct; 39(4):463-8. PubMed ID: 12203665
[TBL] [Abstract][Full Text] [Related]
2. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
Voravud N; Sriuranpong V; Suwanrusme H
J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
[TBL] [Abstract][Full Text] [Related]
3. Interventions for anemia in pediatric cancer patients.
Ruggiero A; Riccardi R
Med Pediatr Oncol; 2002 Oct; 39(4):451-4. PubMed ID: 12203662
[TBL] [Abstract][Full Text] [Related]
4. Is epoetin alfa a treatment option for chemotherapy-related anemia in children?
Büyükpamukçu M; Varan A; Kutluk T; Akyüz C
Med Pediatr Oncol; 2002 Oct; 39(4):455-8. PubMed ID: 12203663
[TBL] [Abstract][Full Text] [Related]
5. Incidence of anemia in pediatric cancer patients in Europe: results of a large, international survey.
Michon J
Med Pediatr Oncol; 2002 Oct; 39(4):448-50. PubMed ID: 12203661
[TBL] [Abstract][Full Text] [Related]
6. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
Patton J; Kuzur M; Liggett W; Miranda F; Varsos H; Porter L
Oncologist; 2004; 9(1):90-6. PubMed ID: 14755018
[TBL] [Abstract][Full Text] [Related]
7. The role of recombinant erythropoietin in childhood cancer.
Shankar AG
Oncologist; 2008 Feb; 13(2):157-66. PubMed ID: 18305061
[TBL] [Abstract][Full Text] [Related]
8. Prior red blood cell transfusions in cancer patients increase the risk of subsequent transfusions with or without recombinant human erythropoietin management.
Couture F; Turner AR; Melosky B; Xiu L; Plante RK; Lau CY; Quirt I
Oncologist; 2005 Jan; 10(1):63-71. PubMed ID: 15632253
[TBL] [Abstract][Full Text] [Related]
9. Increased hemoglobin levels and improved quality-of-life assessments during epoetin alfa treatment in anemic cancer patients: results of a prospective, multicenter German trial.
Reinhardt U; Tulusan A; Angermund R; Lutz H;
Oncologist; 2005 Mar; 10(3):225-37. PubMed ID: 15793226
[TBL] [Abstract][Full Text] [Related]
10. Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy.
Shasha D; George MJ; Harrison LB
Cancer; 2003 Sep; 98(5):1072-9. PubMed ID: 12942577
[TBL] [Abstract][Full Text] [Related]
11. Early epoetin alfa treatment in children with solid tumors.
Zoubek A; Kronberger M
Med Pediatr Oncol; 2002 Oct; 39(4):459-62. PubMed ID: 12203664
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.
Wright JR; Ung YC; Julian JA; Pritchard KI; Whelan TJ; Smith C; Szechtman B; Roa W; Mulroy L; Rudinskas L; Gagnon B; Okawara GS; Levine MN
J Clin Oncol; 2007 Mar; 25(9):1027-32. PubMed ID: 17312332
[TBL] [Abstract][Full Text] [Related]
13. Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy.
Littlewood TJ; Nortier J; Rapoport B; Pawlicki M; de Wasch G; Vercammen E; Schuette W; Wils J; Freund M;
Hematol Oncol; 2003 Dec; 21(4):169-80. PubMed ID: 14735555
[TBL] [Abstract][Full Text] [Related]
14. Clinical experience with epoetin alfa in the management of hemoglobin levels in orthopedic surgery and cancer. Implications for use in gynecologic surgery.
Stovall TG
J Reprod Med; 2001 May; 46(5 Suppl):531-8. PubMed ID: 11396387
[TBL] [Abstract][Full Text] [Related]
15. Early Intervention with epoetin alfa during platinum-based chemotherapy: an analysis of quality-of-life results of a multicenter, randomized, controlled trial compared with population normative data.
Savonije JH; van Groeningen CJ; Wormhoudt LW; Giaccone G
Oncologist; 2006 Feb; 11(2):197-205. PubMed ID: 16476840
[TBL] [Abstract][Full Text] [Related]
16. Anemia of cancer patients: patient selection and patient stratification for epoetin treatment.
Ludwig H; Fritz E
Semin Oncol; 1998 Jun; 25(3 Suppl 7):35-8. PubMed ID: 9671328
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
18. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
[TBL] [Abstract][Full Text] [Related]
19. Role of epoetin in the management of anaemia in patients with lung cancer.
Morère JF
Lung Cancer; 2004 Nov; 46(2):149-56. PubMed ID: 15474662
[TBL] [Abstract][Full Text] [Related]
20. Experience with epoetin alfa and acquired immunodeficiency syndrome anemia.
Henry DH
Semin Oncol; 1998 Jun; 25(3 Suppl 7):64-8. PubMed ID: 9671334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
